

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Kelderman Kim</u> (Last) (First) (Middle) 614 MCKINLEY PLACE NE (Street) MINNEAPOLIS MN 55413 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [TECH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 01/27/2025	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/27/2025		M		13,392	A	\$37.7	52,396	D	
Common Stock	01/27/2025		S		11,731	D	\$77.1915 ⁽¹⁾	40,665	D	
Common Stock	01/27/2025		S		1,661	D	\$77.953 ⁽²⁾	39,004	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$37.7	01/27/2025		M			13,392	(3)	05/01/2025	Common Stock	13,392	\$0	0	D	
Stock Option (Right to Buy)	\$44.33							(3)	08/08/2025	Common Stock	84,308		84,308	D	
Stock Option (Right to Buy)	\$47.6							(3)	08/07/2026	Common Stock	109,536		109,536	D	
Stock Option (Right to Buy)	\$66.97							(3)	08/05/2027	Common Stock	115,724		115,724	D	
Stock Option (Right to Buy)	\$120.46							(4)	08/06/2028	Common Stock	25,944		25,944	D	
Performance Restricted Stock Units	(5)							(6)	(6)	Common Stock	6,984		6,984	D	
Performance Stock Options (Right to Buy)	\$94.52							(6)	08/15/2029	Common Stock	21,704		21,704	D	
Stock Options (Right to Buy)	\$94.52							(7)	08/15/2029	Common Stock	28,940		28,940	D	
Performance Restricted Stock Units	(5)							(8)	(8)	Common Stock	8,873		8,873	D	
Performance Stock Options (Right to Buy)	\$84.61							(8)	08/15/2030	Common Stock	23,881		23,881	D	
Stock Options (Right to Buy)	\$84.61							(9)	08/15/2030	Common Stock	29,391		29,391	D	
Stock Options (Right to Buy)	\$52.83							(10)	11/01/2030	Common Stock	38,252		38,252	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance Restricted Stock Units	(5)							(8)	(8)	Common Stock	9,423		9,423	D	
Performance Stock Options (Right to Buy)	\$68.54							(8)	02/01/2031	Common Stock	25,945		25,945	D	
Stock Options (Right to Buy)	\$68.54							(11)	02/01/2031	Common Stock	51,890		51,890	D	
Performance Restricted Stock Units	(5)							(12)	(12)	Common Stock	51,261		51,261	D	
Restricted Stock Units	(5)							(13)	(13)	Common Stock	25,630		25,630	D	
Stock Options (Right to Buy)	\$74.91							(14)	08/15/2034	Common Stock	69,061		69,061	D	

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.67 to \$77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$77.69 to \$78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Fully exercisable.
- Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
- Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.

/s/ Andrew Nick, Attorney-in-Fact
for Kim Kelderman pursuant to
Power of Attorney previously
filed.

01/29/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.